Neuronascent Inc., a clinical-stage pharmaceutical company developing first-in-class neuron generating therapeutics, today announced the completion of its Phase 1a trial of NNI-362 for Alzheimer’s disease.
| ROCKVILLE, Md., Sept. 29, 2021 /PRNewswire/ -- NeuroNascent, Inc., a clinical-stage pharmaceutical company developing first-in-class neuron generating therapeutics, today announced the completion of its Phase 1a trial of NNI-362 for Alzheimer’s disease. This placebo-controlled, randomized trial was fully supported by a grant from the National Institute on Aging (NIA), part of the National Institutes of Health. The primary goal of this trial was to assess the safety and tolerability of oral NNI-362 in a healthy aged population of subjects 50-72 years of age. In topline results, oral liquid-formulated NNI-362 administration in single and multiple ascending doses never reached a Maximum Tolerated Dose (MTD). NNI-362, administered from 10 to 240 milligrams orally, once daily, showed no serious adverse events and no dose-dependent adverse events. This Phase 1a trial enrolled 56 subjects who were randomized to receive placebo or NNI-362. Neuronascent studied a lipid formulation and an aqueous formulation in this Phase 1a trial. Any potential drug-related adverse events were of a mild-grade and corrected themselves without concomitant medication, and no subject dropped from these studies. The use of an aged population, with greater than 60% female volunteers, modeled the targeted Alzheimer’s disease patient population. Alzheimer’s is a disease of aging, the greatest risk-factor, but there is not a single therapy available to halt or reverse this chronic neurodegenerative disorder. There remains significant unmet need for a disease-modifying treatment for the 5.3 million patients in the US suffering from this debilitating disorder NNI-362 targets adult-born neuron regeneration through a unique mechanism to promote translation (Sumien et al., 2021: https://doi.org/10.1186/s13287-020-02126-3) in models of age-related disorders. This disease-agnostic neuron replacement / enhancement therapy aims to be a first-in-class oral therapy to halt and reverse Alzheimer’s and age-related behavioral deficits. “Research to discover treatments for Alzheimer’s disease, and associated cognitive decline and dementia should not be restricted to anti-amyloid approaches. Instead, we must seek multiple novel treatment strategies – particularly those with the potential to preserve and even restore cognitive function that can be lost with aging and neurodegeneration,” noted R. Scott Turner, MD, PhD, Director of the Memory Disorders Program, Georgetown University, and the newest member of the Neuronascent Scientific Advisory Board. He went on to state, “The innovative therapy developed by Neuronascent (NNI-362) shows promising results in animal models of aging and disease. We are excited as this innovative compound moves forward toward proof-of-concept clinical trials.” Dr. Turner will be presenting this data at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in November 2021 as one of the accepted late breaking posters. “We certainly appreciate each of the numerous volunteers involved in this safety/tolerability trial who consented to test Neuronascent’s first-in-class neuron regenerative therapy. We were pleased to learn that even in the highest dosing group (240mg) a “maximum tolerated dose” was never reached, reflecting the safety and tolerability that had been documented in preclinical animal studies. This is very encouraging as we move toward a Phase 2 proof-of-concept trial in mild to moderate AD patients,” stated founder and CEO, Judith Kelleher-Andersson, PhD. The research reported in this press release was supported by NIA under award number R01AG056561. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. About NNI-362 About Neuronascent, Inc. Safe Harbor Statement Corporate Contact: Media Contact:
SOURCE Neuronascent Inc. |
View original content:
